Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Treatment With Aastrom's Ixmyelocel-T Shown to Reduce Incidence of Major Adverse Cardiovascular Events in Patients With Ischemic
Treatment With Aastrom's Ixmyelocel-T Shown to Reduce Incidence of Major Adverse Cardiovascular Events in Patients With Ischemic
Treatment With Aastrom's Ixmyelocel-T Shown to Reduce Incidence of Major Adverse Cardiovascular Events in Patients With Ischemic
Submitted by
admin
on August 22, 2014 - 12:08pm
Source:
Yahoo
News Tags:
Aastrom Biosciences
ixmyelocel-T
ischemic dilated cardiomyopathy
Headline:
Treatment With Aastrom's Ixmyelocel-T Shown to Reduce Incidence of Major Adverse Cardiovascular Events in Patients With Ischemic
Do Not Allow Advertisers to Use My Personal information
